Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.


Aspirin may treat colon cancer

25 October 2012, 08:14

Aspirin, one of the world's oldest and cheapest drugs, has shown remarkable promise in treating colon cancer in people with mutations in a gene that's thought to play a role in the disease.

Among patients with the mutations, those who regularly took aspirin lived longer than those who didn't, a major study found. Five years after their cancers were diagnosed, 97% of the aspirin users were still alive versus 74% of those not taking the drug.

Aspirin seemed to make no difference in patients who did not have the mutations.

What the study showed

This sort of study can't prove that aspirin caused the better survival, and doctors say more research must confirm the findings before aspirin can be recommended more widely. The study wasn't designed to test aspirin; people were taking it on their own for various reasons.

Still, the results suggest that this simple medicine might be the cheapest gene-targeting therapy ever found for cancer. About one-sixth of all colon cancer patients have the mutated gene and might be helped by aspirin. And aspirin costs just pennies a day.

"It's exciting to think that something that's already in the medicine cabinet may really have an important effect" beyond relieving pain and helping to prevent heart attacks, said Dr Andrew Chan of Massachusetts General Hospital. He and others from Harvard Medical School led the study, which appears in the New England Journal of Medicine.

Colon cancer a growing problem

Cancers of the colon or rectum are a leading cause of cancer deaths worldwide. More than 140 000 new cases and 51 000 deaths from them are expected this year in the United States.

Several studies suggest that aspirin may help fight cancer, especially colorectal tumours. It is often recommended for people who have colon cancer and others at high risk of developing it. But it's not advised for wider use, or for cancer prevention, because it can cause serious bleeding in the stomach and gut.

What has been lacking, doctors say, is a good way to tell which people might benefit the most, so aspirin's risks would be justified. Chan's study suggests a way to do that.

It involved 964 people diagnosed with various stages of colon cancer who were among nearly 175,000 participants in two health studies based at Harvard that began in the 1980s. Every two years, they filled out surveys on their health habits, including aspirin use.

Most had surgery for their cancer, and many also had chemotherapy. They gave tumour tissue samples that could be tested for gene activity. Researchers focused on one gene, PIK3CA, that is involved in a key pathway that fuels cancer's growth and spread. Aspirin seems to blunt that pathway, so the scientists looked at its use in relation to the gene.

In those whose tumours had a mutation in that gene, regular aspirin use cut the risk of dying of colon cancer by 82% and of dying of any cause by 46% during the study period of about 13 years.

Only two of the 62 regular aspirin users whose tumours had the mutated gene died within five years of their cancer diagnosis versus 23 of 90 non-aspirin users with such a mutation.

Results 'exciting'

The results are "quite exciting," said Dr Boris Pasche, a cancer specialist at the University of Alabama at Birmingham who wrote an editorial that appears with the study in the medical journal. Half a dozen drugs are used to treat colon cancer, but only one meaningfully extends survival in people whose cancers have not widely spread, he said.

"Now we may have aspirin. That's why it's a big deal," Pasche said.

In the study, the dose of aspirin — baby or regular — didn't seem to matter, just whether any aspirin was regularly used.

The test for the gene is not expensive and is simple enough that most cancer centres should be able to do it, Chan and Pasche said.

The National Institutes of Health and several foundations paid for the study. One of the 17 authors consults for Bayer, a leading aspirin maker. Pasche has been a paid speaker for two companies that make cancer treatments and has two patent applications under review related to cancer treatment.

Researchers warn that aspirin may not be responsible for the improved survival seen in this study. Differences in how the patients' cancer was treated could have played a role.

For that reason, they say the next step should be a study where some people with the mutated gene are given aspirin and others are not, so their cancer outcomes can be compared more directly.

- AP


Read News24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Read more from our Users

Nigeria @ 56: Words to my green f...

A leader’s job is not to dictate, but rather to be respected, admired and be a trustee, of the land we love, with so much potential, a land which should be freer than free. Its still a long way to fufilling our destiny! Read more...

Submitted by
Isaac Asabor263
Recession: An opportunity for Nig...

The recession should be seen as an opportunity for the country’s promotion as long as we all collectively conduct ourselves in a patriotic manner, writes Isaac Asabor.  Read more...

Submitted by
Black and White

We want to imitate the whites in everything because we are ignorant of our inherent originality and content. We spend all our Naira to acquire his inventions because we so oblivious of our natural endowments that we allow him have it for free. Read more...

Submitted by
Nate Nat
Adamawa State University Mubi: A ...

ADSU integrity forum has accused the Sunday Joshua Wugira, a lawyer, of adopting unorthodox tactics by abusing his privilege by attacking the integrity of ADSU Vice Chancellor Dr. Moses Zira Zaruwa, writes a News24 reader. Read more...

Submitted by
Abdulsalam Jubril
My Country Nigeria (Part One)

Poetry by Abdulsalam Jubril.

Submitted by
Abdulsalam Jubril
Recession, dearth in leadership a...

Every leader has the opportunity to become great and making himself immortal in the lives and hearts of people for generations to come. Will Mr. President seize this opportunity?, questions Abdulsalam Jubril. Read more...